person · Reporting owner

DOBMEIER ERIC

Disclosed activity across 9 companies

Tapewire entity: 36738
SEC CIK: 0001202785

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Adaptive Biotechnologies CorpADPT · Entity 1126	Director	February 14, 2021	February 18, 2021
Aravive, Inc.VSAR · Entity 114535	Director	December 20, 2017	December 22, 2017
Atara Biotherapeutics, Inc.ATRA · Entity 6828	Director	November 10, 2023	November 14, 2023
Jade Biosciences, Inc.JBIO · Entity 4757	Director	June 09, 2026	June 11, 2026
Janux Therapeutics, Inc.JANX · Entity 4864	Director	June 11, 2026	June 13, 2026
STEMLINE THERAPEUTICS INCSTML · Entity 148550	Director	June 19, 2017	June 20, 2017
Seagen Inc.SGEN · Entity 13956	Chief Operating Officer	December 04, 2017	December 06, 2017
Structure Therapeutics Inc.GPCR · Entity 1222	Director	June 17, 2026	June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adaptive Biotechnologies Corp

Report date February 14, 2021 · Filed February 18, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,504	Reported balance After 2021-02-14 transaction · row 1 1 source row Row 1 · 2021-02-14 · Grant · Acquired 1,504 · Balance 1,504
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.50 · Expires 2031-02-14	Direct	3,759	Reported balance After 2021-02-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-02-14 · Grant · Acquired 3,759 · Balance 3,759 F1: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date.

Aravive, Inc.

Report date December 20, 2017 · Filed December 22, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,160	Reported balance After 2017-12-20 transaction · row 1 1 source row Row 1 · 2017-12-20 · Grant · Acquired 11,200 · Balance 18,160 F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018.

Atara Biotherapeutics, Inc.

Report date November 10, 2023 · Filed November 14, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	563,325	Reported balance After 2023-11-10 transaction · row 1 1 source row Row 1 · 2023-11-10 · Purchase · Acquired 446,825 · Balance 563,325 F1: Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.2235 to $0.2298. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.2235 to $0.2298. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

Jade Biosciences, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.22 · Expires 2036-06-08	Direct	34,843	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 34,843 · Balance 34,843 F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Janux Therapeutics, Inc.

Report date June 11, 2026 · Filed June 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,481	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Grant · Acquired 5,500 · Balance 15,481 F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.66 · Expires 2036-06-10	Direct	15,500	Reported balance After 2026-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-11 · Grant · Acquired 15,500 · Balance 15,500 F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date.

F2: The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.

STEMLINE THERAPEUTICS INC

Report date June 19, 2017 · Filed June 20, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	27,963	Reported balance After 2017-06-19 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-06-19 · Grant · Acquired 10,000 · Balance 27,963 F1: The restricted shares will vest according to the following schedule: 3,334 shares on 6/19/2018, 3,333 shares on 6/19/2019 and 3,333 shares on 6/19/2020. F2: Of the 27,963 shares, 16,666 shares are restricted stock.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2027-06-19	Direct	24,000	Reported balance After 2017-06-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-06-19 · Grant · Acquired 24,000 · Balance 24,000 F3: The options will vest according to the following schedule: one-third on each of 6/19/2018, 6/19/2019, and 6/19/2020.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted shares will vest according to the following schedule: 3,334 shares on 6/19/2018, 3,333 shares on 6/19/2019 and 3,333 shares on 6/19/2020.

F2: Of the 27,963 shares, 16,666 shares are restricted stock.

F3: The options will vest according to the following schedule: one-third on each of 6/19/2018, 6/19/2019, and 6/19/2020.

Seagen Inc.

Report date December 04, 2017 · Filed December 06, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	119,860	Last balance in matching sequence After 2017-12-04 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2017-12-04 · Exercise / conversion · Acquired 3,729 · Balance 121,153 F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Row 2 · 2017-12-04 · Sale · Disposed 3,729 · Balance 117,424 F2: Reflects sales of common stock executed in multiple transactions at prices ranging from $58.53 to $58.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Row 3 · 2017-12-04 · Exercise / conversion · Acquired 2,436 · Balance 119,860 F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.04 · Expires 2023-08-19	Direct	0	Reported balance After 2017-12-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-12-04 · Exercise / conversion · Disposed 2,436 · Balance 0 F3: Shares vested at a rate of 25% on 8/19/14 and monthly thereafter until all the shares were fully vested on 8/19/17.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.10 · Expires 2022-08-20	Direct	24,700	Reported balance After 2017-12-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-12-04 · Exercise / conversion · Disposed 3,729 · Balance 24,700 F4: Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/16.

Filing footnotes · ownership attribution and instrument terms

F1: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.

F2: Reflects sales of common stock executed in multiple transactions at prices ranging from $58.53 to $58.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: Shares vested at a rate of 25% on 8/19/14 and monthly thereafter until all the shares were fully vested on 8/19/17.

F4: Shares vested at a rate of 25% on 8/20/13 and monthly thereafter until all the shares were fully vested on 8/20/16.

Structure Therapeutics Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16	Direct	39,453	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").

F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,

F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CHINOOK THERAPEUTICS, INC.

Report date August 11, 2023 · Filed August 11, 2023

Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-08-11 transaction · row 1 1 source row Row 1 · 2023-08-11 · Disposition to issuer · Disposed 301,138 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2029-06-05	Direct	Reported balance After 2023-08-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-08-11 · Disposition to issuer · Disposed 353,358 · Balance 0 F2: This stock option award, which provided for 25% of the award to vest on April 1, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2030-03-17	Direct	Reported balance After 2023-08-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-08-11 · Disposition to issuer · Disposed 313,555 · Balance 0 F3: This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05	Direct	Reported balance After 2023-08-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-08-11 · Disposition to issuer · Disposed 271,647 · Balance 0 F4: This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.14 · Expires 2031-02-09	Direct	Reported balance After 2023-08-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-08-11 · Disposition to issuer · Disposed 178,600 · Balance 0 F5: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.90 · Expires 2032-01-30	Direct	Reported balance After 2023-08-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-08-11 · Disposition to issuer · Disposed 300,000 · Balance 0 F6: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.27 · Expires 2033-01-30	Direct	Reported balance After 2023-08-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-08-11 · Disposition to issuer · Disposed 255,150 · Balance 0 F7: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-08-11 · Disposition to issuer · Disposed 30,797 · Balance 0 F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F9: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-08-11 · Disposition to issuer · Disposed 20,248 · Balance 0 F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-08-11 · Disposition to issuer · Disposed 50,001 · Balance 0 F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-08-11 · Disposition to issuer · Disposed 64,050 · Balance 0 F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F12: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2023-08-11 · Disposition to issuer · Disposed 11,300 · Balance 0 F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F13: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

F2: This stock option award, which provided for 25% of the award to vest on April 1, 2020 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F3: This stock option award, which provided for 25% of the award to vest on March 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F4: This stock option award, which provided for 25% of the award to vest on October 6, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F5: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F6: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F7: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F8: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F9: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on October 6, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F12: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F13: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 01, 2022 Filed Dec 2, 2022 16:26 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GiftCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-059418 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,676 Read SEC document
October 06, 2022 Filed Oct 11, 2022 16:33 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionRestricted Stock Units (RSU) · Derivative	30,796	$0.00	$0.00	Disclosure SEC source: 0001209191-22-053303 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,797 Underlying: Common Stock · 30,796 shares Expires 2030-10-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
October 06, 2022 Filed Oct 11, 2022 16:33 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	30,796	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-053303 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 23, 2022 Filed Jun 27, 2022 20:48 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	31,500	$0.00 Strike: $7.35	$0.00	Disclosure SEC source: 0001140361-22-024160 · form4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2032-06-22 F2 · derivative.exercise_date: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
June 23, 2022 Filed Jun 27, 2022 20:48 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	20,500	$0.00	$0.00	Disclosure SEC source: 0001140361-22-024160 · form4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,500 F1 · shares: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
May 25, 2022 Filed May 27, 2022 18:17 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	5,000	$13.03	$65,147.50	Disclosure SEC source: 0001209191-22-032707 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,880 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.80 to $13.2974, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document
February 10, 2022 Filed Feb 14, 2022 19:54 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionRestricted Stock Units (RSU) · Derivative	20,247	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009561 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,496 Underlying: Common Stock · 20,247 shares Expires 2024-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
February 10, 2022 Filed Feb 14, 2022 19:54 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	20,247	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-009561 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 31, 2022 Filed Feb 2, 2022 17:25 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantRestricted Stock (RSU)(Common Stock) · Derivative	75,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-006451 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2025-01-31 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
January 31, 2022 Filed Feb 2, 2022 17:25 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantStock Option (right to buy) · Derivative	300,000	$0.00 Strike: $12.90	$0.00	Disclosure SEC source: 0001209191-22-006451 · doc4.xml · derivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 31, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
December 23, 2021 Filed Dec 27, 2021 18:24 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $0.35	$0.00	Disclosure SEC source: 0001209191-21-071297 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,358 Underlying: Common Stock · 40,000 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested as to 25% of the total shares on April 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document
December 23, 2021 Filed Dec 27, 2021 18:24 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	40,000	$0.35	$14,000.00	Disclosure SEC source: 0001209191-21-071297 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 06, 2021 Filed Oct 8, 2021 18:49 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionRestricted Stock Units (RSU) · Derivative	30,796	$0.00	$0.00	Disclosure SEC source: 0001209191-21-060113 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,593 Underlying: Common Stock · 30,796 shares Expires 2030-10-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
October 06, 2021 Filed Oct 8, 2021 18:49 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	30,796	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-060113 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
September 20, 2021 Filed Sep 22, 2021 19:23 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	2,000	$12.00	$24,000.00	Disclosure SEC source: 0001209191-21-057315 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,837 Read SEC document
August 19, 2021 Filed Aug 19, 2021 17:55 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	3,000	$12.00	$36,000.00	Disclosure SEC source: 0001209191-21-052605 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,837 Read SEC document
August 18, 2021 Filed Aug 19, 2021 17:55 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	7,000	$11.74	$82,163.20	Disclosure SEC source: 0001209191-21-052605 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,837 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.45 to $12.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document
June 14, 2021 Filed Jun 15, 2021 17:24 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.35	$0.00	Disclosure SEC source: 0001209191-21-040659 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,358 Underlying: Common Stock · 20,000 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested as to 25% of the total shares on April 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document
June 14, 2021 Filed Jun 15, 2021 17:24 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	20,000	$0.35	$7,000.00	Disclosure SEC source: 0001209191-21-040659 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 08, 2021 Filed Jun 9, 2021 23:07 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $13.80	$0.00	Disclosure SEC source: 0001140361-21-020435 · form4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-07 F2 · derivative.exercise_date: The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
June 08, 2021 Filed Jun 9, 2021 23:07 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	11,000	$0.00	$0.00	Disclosure SEC source: 0001140361-21-020435 · form4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 F1 · shares: These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
May 14, 2021 Filed May 18, 2021 17:01 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	1,000	$14.44	$14,440.00	Disclosure SEC source: 0001209191-21-033574 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,837 F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document
February 14, 2021 Filed Feb 18, 2021 01:01 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	GrantStock Option (Right to Buy) · Derivative	3,759	$0.00 Strike: $66.50	$0.00	Disclosure SEC source: 0001209191-21-011549 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,759 Underlying: Common Stock · 3,759 shares Expires 2031-02-14 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document
February 14, 2021 Filed Feb 18, 2021 01:01 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	GrantCommon Stock	1,504	$0.00	$0.00	Disclosure SEC source: 0001209191-21-011549 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 Read SEC document
February 10, 2021 Filed Feb 12, 2021 18:08 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantRestricted Stock (RSU)(Common Stock) · Derivative	60,743	$0.00	$0.00	Disclosure SEC source: 0001209191-21-010383 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,743 Underlying: Common Stock · 60,743 shares Expires 2024-02-10 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
February 10, 2021 Filed Feb 12, 2021 18:08 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantStock Option (right to buy) · Derivative	178,600	$0.00 Strike: $15.14	$0.00	Disclosure SEC source: 0001209191-21-010383 · doc4.xml · derivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,600 Underlying: Common Stock · 178,600 shares Expires 2031-02-09 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 10, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
January 04, 2021 Filed Jan 7, 2021 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $6.32	$0.00	Disclosure SEC source: 0001209191-21-002379 · doc4.xml · derivative · entry 6 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 10,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document
January 04, 2021 Filed Jan 7, 2021 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	400	$59.46	$23,784.00	Disclosure SEC source: 0001209191-21-002379 · doc4.xml · nonDerivative · entry 5 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. Read SEC document
January 04, 2021 Filed Jan 7, 2021 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	592	$58.67	$34,732.64	Disclosure SEC source: 0001209191-21-002379 · doc4.xml · nonDerivative · entry 4 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.395 to 59.27, inclusive. Read SEC document
January 04, 2021 Filed Jan 7, 2021 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	5,725	$57.76	$330,676.00	Disclosure SEC source: 0001209191-21-002379 · doc4.xml · nonDerivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 992 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.27 to 58.18, inclusive. Read SEC document
January 04, 2021 Filed Jan 7, 2021 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	3,283	$56.10	$184,176.30	Disclosure SEC source: 0001209191-21-002379 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,717 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.67 to 56.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document
January 04, 2021 Filed Jan 7, 2021 01:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionCommon Stock	10,000	$6.32	$63,200.00	Disclosure SEC source: 0001209191-21-002379 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. Read SEC document
December 21, 2020 Filed Dec 22, 2020 19:47 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $0.35	$0.00	Disclosure SEC source: 0001209191-20-064942 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,358 Underlying: Common Stock · 20,000 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested as to 25% of the total shares on April 1, 2020, and thereafter vests as to 1/48 of the total shares on a monthly basis until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document
December 21, 2020 Filed Dec 22, 2020 19:47 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	20,000	$0.35	$7,000.00	Disclosure SEC source: 0001209191-20-064942 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 09, 2020 Filed Dec 10, 2020 17:38 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	2,000	$13.08	$26,150.00	Disclosure SEC source: 0001209191-20-062761 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,837 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document
December 08, 2020 Filed Dec 10, 2020 17:38 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	2,000	$13.24	$26,483.40	Disclosure SEC source: 0001209191-20-062761 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,837 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.2333 to $13.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document
November 23, 2020 Filed Nov 23, 2020 19:26 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	929	$13.67	$12,698.78	Disclosure SEC source: 0001209191-20-060088 · doc4.xml · nonDerivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,837 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.60 to $13.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document
November 20, 2020 Filed Nov 23, 2020 19:26 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	571	$13.69	$7,816.99	Disclosure SEC source: 0001209191-20-060088 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,908 F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document
November 19, 2020 Filed Nov 23, 2020 19:26 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	500	$13.50	$6,750.00	Disclosure SEC source: 0001209191-20-060088 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,337 F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document
November 11, 2020 Filed Nov 13, 2020 18:13 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	2,500	$13.75	$34,375.00	Disclosure SEC source: 0001209191-20-058367 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,837 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.65 to $13.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document
November 10, 2020 Filed Nov 13, 2020 18:13 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	PurchaseCommon Stock	2,000	$13.86	$27,720.00	Disclosure SEC source: 0001209191-20-058367 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,337 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.75 to $14.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document
October 06, 2020 Filed Oct 7, 2020 20:57 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantRestricted Stock (RSU) (Common Stock) · Derivative	92,389	$0.00	$0.00	Disclosure SEC source: 0001209191-20-054245 · doc4.xml · derivative · entry 5 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,389 Underlying: Common Stock · 92,389 shares Expires 2030-10-05 F8 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement. F9 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
October 06, 2020 Filed Oct 7, 2020 20:57 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantStock Option (right to buy) · Derivative	271,647	$0.00 Strike: $14.77	$0.00	Disclosure SEC source: 0001209191-20-054245 · doc4.xml · derivative · entry 4 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,647 Underlying: Common Stock · 271,647 shares Expires 2030-10-05 F7 · derivative.exercise_date: The stock option vests as to 25% of the total shares on October 6, 2021, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
October 05, 2020 Filed Oct 7, 2020 20:57 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantStock Option (right to buy) · Derivative	423,555	Not disclosed Strike: $0.42	Not disclosed	Disclosure SEC source: 0001209191-20-054245 · doc4.xml · derivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,555 Underlying: Common Stock · 423,555 shares Expires 2030-03-17 F6 · price: Received in connection with the Merger in exchange for a stock option to acquire 1,449,600 shares of Private Chinook common stock for $0.12 per share. F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
October 05, 2020 Filed Oct 7, 2020 20:57 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantStock Option (right to buy) · Derivative	463,358	Not disclosed Strike: $0.35	Not disclosed	Disclosure SEC source: 0001209191-20-054245 · doc4.xml · derivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,358 Underlying: Common Stock · 463,358 shares Expires 2029-06-05 F4 · price: Received in connection with the merger of Private Chinook into the Issuer (the "Merger") in exchange for a stock option to acquire 1,585,822 shares of Private Chinook common stock for $0.10 per share. F3 · derivative.exercise_date: The stock option vested as to 25% of the total shares on April 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
October 05, 2020 Filed Oct 7, 2020 20:57 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantCommon Stock	46,337	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-054245 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,337 F1 · shares: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. F2 · price: The shares reported represent the number of shares of Issuer common stock received by the Reporting Person on the Effective Date in connection with the merger of Chinook Therapeutics U.S., Inc. ("Private Chinook") into the Issuer. Read SEC document
October 01, 2020 Filed Oct 2, 2020 23:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $6.32	$0.00	Disclosure SEC source: 0001209191-20-053370 · doc4.xml · derivative · entry 4 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 10,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document
October 01, 2020 Filed Oct 2, 2020 23:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	776	$49.21	$38,186.96	Disclosure SEC source: 0001209191-20-053370 · doc4.xml · nonDerivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.00 to 49.34, inclusive. Read SEC document
October 01, 2020 Filed Oct 2, 2020 23:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	SaleCommon Stock	9,224	$48.47	$447,087.28	Disclosure SEC source: 0001209191-20-053370 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.155 to 48.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document
October 01, 2020 Filed Oct 2, 2020 23:00 UTC	Adaptive Biotechnologies Corp ADPT · Entity 1126	Exercise / conversionCommon Stock	10,000	$6.32	$63,200.00	Disclosure SEC source: 0001209191-20-053370 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.